Graviton, Author at Sagimet Biosciences

Sagimet Biosciences Announces Appointment of David Happel to Chief Executive Officer; Dr. George Kemble to Transition to Executive Chairman Role

By Graviton / 10/2022

San Mateo, California, October 24, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways,

Author name: Graviton

Serum proteomic profiling reveals that the fatty acid synthase (FASN) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (FGF19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (HMGCS1) in NASH patients

Sagimet Biosciences Announces Late-Breaking, Oral and Poster Presentations for Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in NASH at AASLD’s The Liver Meeting

Sagimet Biosciences Announces Appointment of David Happel to Chief Executive Officer; Dr. George Kemble to Transition to Executive Chairman Role

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Sagimet Biosciences Announces Completion of Patient Enrollment in Phase 2b ‘FASCINATE-2’ Clinical Trial with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Non-alcoholic Steatohepatitis

Sagimet Biosciences Announces Oral Presentation on Denifanstat at Keystone Symposia in Nonalcoholic Steatohepatitis (NASH)

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study

Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL’s International Liver Congress (ILC) 2022

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640: efficacy, safety and biomarker results from a global phase 2 randomized pbo-controlled NASH trial, FASCINATE-1

Site map

Contact us